We are live on
!
Find out more
AGP
Aspire Growth Partners Portfolio holdings
AUM
$172M
1-Year Est. Return
33.61%
This Fund
S&P 500
This Quarter
Est. Return
-2.53%
1 Year Est. Return
+33.61%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$113M
AUM Growth
+$10.5M
(+10%)
Cap. Flow
+$15.3M
Cap. Flow
% of AUM
13.56%
Top 10 Holdings %
Top 10 Hldgs %
44.69%
Holding
116
New
17
Increased
67
Reduced
27
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Capital Group Core Equity ETF
CGUS
|
+$2.22M |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$1.87M |
| 3 |
Eaton
ETN
|
+$1.07M |
| 4 |
Trane Technologies
TT
|
+$997K |
| 5 |
Capital Group Dividend Value ETF
CGDV
|
+$949K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IQVIA
IQV
|
+$241K |
| 2 |
Thermo Fisher Scientific
TMO
|
+$219K |
| 3 |
Bristol-Myers Squibb
BMY
|
+$208K |
| 4 |
Nucor
NUE
|
+$101K |
| 5 |
iShares MSCI USA Momentum Factor ETF
MTUM
|
+$98.3K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.81% |
| 2 | Financials | 6.96% |
| 3 | Healthcare | 5.89% |
| 4 | Consumer Discretionary | 5.85% |
| 5 | Industrials | 5.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Edwards Lifesciences
EW
$50.5B
| $238K | 0.21% |
3,171
-28
| -0.9% | -$2K |
|
102
Capital Group Global Growth Equity ETF
CGGO
$11.5B
| $233K | 0.21% |
+8,012
| New | +$238K |
|
103
AutoZone
AZO
$49B
| $232K | 0.21% |
+62
| New | +$214K |
|
104
Raymond James Financial
RJF
$34.3B
| $231K | 0.21% |
1,613
+11
| +0.7% | +$1.71K |
|
105
BP
BP
$114B
| $224K | 0.2% |
+7,955
| New | +$260K |
|
106
Progressive
PGR
$122B
| $217K | 0.19% |
+758
| New | +$198K |
|
107
Amplify CWP Enhanced Dividend Income ETF
DIVO
$7.67B
| $215K | 0.19% |
+5,320
| New | +$220K |
|
108
Howmet Aerospace
HWM
$114B
| $213K | 0.19% |
+1,354
| New | +$172K |
|
109
NextEra Energy
NEE
$180B
| $212K | 0.19% |
3,143
+337
| +12% | +$23.8K |
|
110
Qualcomm
QCOM
$155B
| $203K | 0.18% |
1,407
+101
| +8% | +$16.5K |
|
111
Chipotle Mexican Grill
CMG
$48.2B
| $201K | 0.18% |
3,897
-7
| -0.2% | -$381 |
|
112
Nuveen Preferred & Income Opportunities Fund
JPC
$2.91B
| $92.1K | 0.08% |
+11,773
| New | +$93.9K |
|
113
CytomX Therapeutics
CTMX
$671M
| $88.6K | 0.08% |
92,254
+51,474
| +126% | +$39.9K |
|
|
114
Bristol-Myers Squibb
BMY
$132B
| – | – |
-3,684
| Closed | -$208K |
|
|
115
IQVIA
IQV
$38.4B
| – | – |
-1,226
| Closed | -$241K |
|
|
116
Thermo Fisher Scientific
TMO
$215B
| – | – |
-421
| Closed | -$219K |
|
Similar funds
BIA
CRFG
SPF
TA
GWCM
AIM
BAM
CCM
Aspire Growth Partners's Q1 2025 Portfolio in Review
As of Q1 2025, Aspire Growth Partners held 116 positions worth $113M, up 10% from $102M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Aspire Growth Partners deployed $15.3M of net new capital in Q1 2025, opening 17 new positions and adding to 67 existing holdings. Its largest new stake was Eaton: 3,424 shares worth $1.03M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 22% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Nucor, an estimated $101K trimmed.
- Aspire Growth Partners's largest Q1 2025 buy was Eaton: 3,424 shares worth $1.03M.
- Aspire Growth Partners added most to Capital Group Core Equity ETF in Q1 2025, an estimated $2.22M increase.
- Aspire Growth Partners's biggest Q1 2025 reduction was Nucor, cutting an estimated $101K.
- Aspire Growth Partners fully exited IQVIA in Q1 2025, selling an estimated $241K.
- Aspire Growth Partners's ten largest holdings make up 45% of its $113M portfolio in Q1 2025.
- Aspire Growth Partners opened 17 new positions and closed 3 in Q1 2025.
- Aspire Growth Partners's portfolio value rose 10% quarter-over-quarter to $113M.
Based on Aspire Growth Partners's 13F filing for Q1 2025, filed 14 May 2025.